Loss of base-to-apex circumferential strain gradient assessed by cardiovascular magnetic resonance in Fabry disease: relationship to T1 mapping, late gadolinium enhancement and hypertrophy

Table 1 Baseline characteristics

	Healthy Controls (n = 8)	Fabry Disease Patients (n = 38)	p-value
Age (years)	40.1 ± 13.7	45.0 ± 14.5	0.39
Female	3 (38%)	24 (63%)	0.25
Male	5 (63%)	14 (37%)	0.25
Hematocrit (%)	41 ± 5	41 ± 4	0.96
Height (cm)	168.0 ± 14.0	166.5 ± 9.3	0.71
Weight (kg)	72.3 ± 15.1	75.2 ± 15.8	0.64
BSA (m²)	1.83 ± 0.25	1.85 ± 0.21	0.81
Systolic blood pressure (mmHg)		120.6 ± 15.1
Diastolic blood rpessure (mmHg)		76.9 ± 9.5
Hypertension		13 (34%)
Diabetes mellitus		2 (5%)
Chronic kidney disease		0 (0%)
Medications
Enzyme replacement therapy		13 (34%)
Beta blockers		6 (16%)
Statins		17 (45%)
Calcium channel blocker		4 (11%)
ACEi/ARB		15 (40%)
Aspirin		15 (40%)

Comparisons between groups were made by independent samples t-test, Wilcoxon rank sum test or Fisher’s exact test. Continuous variables are presented as mean ± SD. Categorical variables are presented as number of subjects with percentage in parentheses. ACEi angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, BSA body surface area

ISSN: 1532-429X